Tags

Type your tag names separated by a space and hit enter

MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children.
Allergy. 2016 08; 71(8):1219-22.A

Abstract

The objective was to evaluate the efficacy of MP-AzeFlu (Dymista(®)) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 : 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP-AzeFlu: n = 264; FP: n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff: -0.14; 95% CI: -0.28, -0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days. More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP. MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR.

Authors+Show Affiliations

Division of Basic Clinical Immunology, School of Medicine, University of California, Irvine, CA, USA. Allergy & Asthma Associates, Mission Viejo, CA, USA.University Hospital, Montpellier, France. MACVIA-LR, Contre les Maladies Chronique pour un Vieillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Aging Reference Site, Montpellier, France. INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, U1168, Paris, France. UVSQ UMR-S1168, Universite Versailles St-Quentin-en-Yvelines, Versailles, France.King's College London, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Division of Asthma, Allergy and Lung Biology, Guy's and St Thomas' NHS Foundation Trust, London, UK.Allergology Department, Centre de l'Asthme et des Allergies. Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France.Department of Mother and Child Health, Padua General University Hospital, Padua, Italy.Pediatric Allergy and Pneumology Unit, Children's Hospital La Fe, Valencia, Spain.Department of Lung Disease & Clinical Immunology, University of Turku, Turku, Finland. Terveystalo Allergy Center, Turku, Finland.National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Department of Pediatrics, Sachs' Children's Hospital, Stockholm, Sweden.Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27043452

Citation

Berger, W, et al. "MP-AzeFlu Is More Effective Than Fluticasone Propionate for the Treatment of Allergic Rhinitis in Children." Allergy, vol. 71, no. 8, 2016, pp. 1219-22.
Berger W, Bousquet J, Fox AT, et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016;71(8):1219-22.
Berger, W., Bousquet, J., Fox, A. T., Just, J., Muraro, A., Nieto, A., Valovirta, E., Wickman, M., & Wahn, U. (2016). MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy, 71(8), 1219-22. https://doi.org/10.1111/all.12903
Berger W, et al. MP-AzeFlu Is More Effective Than Fluticasone Propionate for the Treatment of Allergic Rhinitis in Children. Allergy. 2016;71(8):1219-22. PubMed PMID: 27043452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. AU - Berger,W, AU - Bousquet,J, AU - Fox,A T, AU - Just,J, AU - Muraro,A, AU - Nieto,A, AU - Valovirta,E, AU - Wickman,M, AU - Wahn,U, Y1 - 2016/06/01/ PY - 2016/04/01/accepted PY - 2016/4/5/entrez PY - 2016/4/5/pubmed PY - 2017/11/29/medline KW - Dymista KW - MP29-02 KW - children KW - fluticasone propionate SP - 1219 EP - 22 JF - Allergy JO - Allergy VL - 71 IS - 8 N2 - The objective was to evaluate the efficacy of MP-AzeFlu (Dymista(®)) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 : 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP-AzeFlu: n = 264; FP: n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff: -0.14; 95% CI: -0.28, -0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days. More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP. MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/27043452/MP_AzeFlu_is_more_effective_than_fluticasone_propionate_for_the_treatment_of_allergic_rhinitis_in_children_ L2 - https://doi.org/10.1111/all.12903 DB - PRIME DP - Unbound Medicine ER -